Patents Issued in September 15, 2020
  • Patent number: 10774023
    Abstract: A method of producing one or more glycerol ethers, the method comprising contacting glycerol and tertiary butanol (TBA) in the presence of an acidic catalyst to produce one or more glycerol ethers selected from mono-tert butyl glycerol ethers, di-tert butyl glycerol ethers, tri-tert butyl glycerol ethers, or a combination thereof; separating water and a stream comprising isobutylene, unreacted TBA, or a combination thereof from the one or more glycerol ethers; and recycling at least a portion of the stream comprising isobutylene, unreacted TBA, or a combination thereof to the contacting. Also disclosed is a process of co-producing isooctene, wherein the process involves contacting glycerol and tertiary butanol in the presence of a dehydrating catalyst and dimerizing/oligomerizing the dehydrated products in the presence of an oligomerizing catalyst to form isooctene, a precursor of isooctane and isomers thereof.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: September 15, 2020
    Assignee: Lyondell Chemical Technology, L.P.
    Inventors: Sarthak Gaur, Robert John Rebman, Daniel F. White, Joseph P. Longtin
  • Patent number: 10774024
    Abstract: The present invention relates to a catalytic process for preparing an ?,?-ethylenically unsaturated carboxylic acid salt, comprising contacting an alkene and carbon dioxide with a carboxylation catalyst being a transition metal complex, an alkoxide, and an organic solvent, to obtain an ?,?-ethylenically unsaturated carboxylic acid salt, the organic solvent being incompletely miscible with water at a pressure of 1 bar at at least one temperature T and selected from amides and ureas, T being a temperature in the range from 10° C. to 90° C.
    Type: Grant
    Filed: April 4, 2017
    Date of Patent: September 15, 2020
    Assignee: BASF SE
    Inventors: Thomas Schaub, Rocco Paciello, Nuria Huguet Subiela, Oliver Trapp, Simone Manzini
  • Patent number: 10774025
    Abstract: The present invention provides a production method of a multifunctional acrylate with a reduced tin content which includes adding an acid to a mixture containing an organotin compound and a multifunctional acrylate and distilling the mixture containing the acid.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: September 15, 2020
    Assignee: OSAKA ORGANIC CHEMICAL INDUSTRY LTD.
    Inventors: Keisuke Ito, Shigeaki Matsumoto, Keita Shigematsu
  • Patent number: 10774026
    Abstract: A method for producing esters of an alpha, beta-unsaturated carboxylic acid are disclosed, the method includes reacting a three or four carbon beta-hydroxyalkanoate composition or mixtures thereof with a mono-alcohol under heating conditions to form a reaction product and distilling the reaction product to recover a composition containing at least fifty percent by weight of the ester of the alpha, beta-unsaturated carboxylic acid.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: September 15, 2020
    Assignee: CARGILL, INCORPORATED
    Inventors: Timothy Walter Abraham, Ravi R. Gokarn
  • Patent number: 10774027
    Abstract: The present disclosure provides regioselective methods for synthesizing intermediates useful in making prostacyclin derivatives, such as treprostinil.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: September 15, 2020
    Assignee: United Therapeutics Corporation
    Inventors: Hitesh Batra, Sudersan M. Tuladhar, David A. Walsh
  • Patent number: 10774028
    Abstract: A method for producing an asymmetric chain carbonate by reacting an alcohol with a halocarbonate ester compound in the presence of a basic magnesium salt.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: September 15, 2020
    Assignee: DAIKIN INDUSTRIES, LTD.
    Inventors: Tomohito Hamada, Michiaki Okada, Akiyoshi Yamauchi, Yosuke Kishikawa
  • Patent number: 10774029
    Abstract: A compound represented by the formula (I). wherein R1 represents a hydrogen atom, a halogen atom or a C1 to C6 alkyl group that may have a halogen atom; R2 represents a C1 to C12 fluorinated saturated hydrocarbon group; W1 represents a C5 to C18 divalent alicyclic hydrocarbon group; A1 and A2 independently represents a single bond or *-A3-X1-(A4-X2)a—; A3 and A4 independently represents a C1 to C6 alkanediyl group; X1 and X2 independently represents —O—, —CO—O— or —O—CO—; a represents 0 or 1; and * represents a bond to an oxygen atom.
    Type: Grant
    Filed: September 21, 2018
    Date of Patent: September 15, 2020
    Assignee: SUMITOMO CHEMICAL COMPANY, LIMITED
    Inventors: Tatsuro Masuyama, Satoshi Yamamoto, Koji Ichikawa
  • Patent number: 10774030
    Abstract: Disclosed are new classes of diphenol compounds, derived from tyrosol or tyrosol analogues and hydroxybenzoic acid, which are useful as monomers for preparation of biocompatible polymers. Also disclosed are biocompatible polymers prepared from these monomeric diphenol compounds, including novel biodegradable and/or bioresorbable polymers of formula. These biocompatible polymers or polymer compositions with enhanced bioresorbability and processibility are useful in a variety of medical applications, such as in medical devices and controlled-release therapeutic compositions. The invention also provides methods for preparing these monomeric diphenol compounds and biocompatible polymers.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 15, 2020
    Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Durgadas Bolikal, Joachim B. Kohn
  • Patent number: 10774031
    Abstract: The present disclosure discloses prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: September 15, 2020
    Assignee: XW LABORATORIES INC.
    Inventors: Jia-Ning Xiang, Xuesong Xu, Xuan Zhang
  • Patent number: 10774032
    Abstract: Provided herein are metal halide perovskite nanoplatelets, methods for making metal halide perovskite nanoplatelets, and devices and composite materials that include metal halide nanoperovskite nanoplatelets. The metal halide perovskite nanoplatelets may be stable at ambient temperature and pressure, thereby easing device fabrication.
    Type: Grant
    Filed: September 22, 2016
    Date of Patent: September 15, 2020
    Assignee: Florida State University Research Foundation, Inc.
    Inventors: Hanwei Gao, Biwu Ma, Yichuan Ling, Zhao Yuan
  • Patent number: 10774033
    Abstract: Provided herein are methods and intermediates for making (1R,2R,5R)-5-amino-2-methylcyclohexanol hydrochloride, which are useful for the preparation of compounds useful for the treatment of a disease, disorder, or condition associated with the JNK pathway.
    Type: Grant
    Filed: January 28, 2019
    Date of Patent: September 15, 2020
    Assignee: Celgene Corporation
    Inventors: Terrence Joseph Connolly, Hon-Wah Man, Periyandi Nagarajan, Chinnapillai Rajendiran, Jasti Venkateswarlu
  • Patent number: 10774034
    Abstract: The present invention relates to a process for the conversion of ethylene oxide to 2-aminoethanol and/or ethane-1,2-diamine and/or linear polyethylenimines of the formula H2N—(CH2CH2NH)n—CH2CH2—NH2 wherein n?1 comprising (i) providing a catalyst comprising a zeolitic material comprising YO2 and X2O3, wherein Y is a tetravalent element and X is a trivalent element; (ii) providing a gas stream comprising ethylene oxide and ammonia; (iii) contacting the catalyst provided in (i) with the gas stream provided in (ii) for converting ethylene oxide to 2-aminoethanol and/or ethane-1,2-diamine and/or linear polyethylenimines.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: September 15, 2020
    Assignee: BASF SE
    Inventors: Alvaro Gordillo, Andrei-Nicolae Parvulescu, Armin Lange De Oliveira, Andreas Kuschel, Juergen Bechtel, Johannes Lieberknecht, Ulrich Müller, Johann-Peter Melder, Christian Gruenanger
  • Patent number: 10774035
    Abstract: The invention relates to a method for synthesizing amino acids or amino acid derivatives involving cross metathesis of functionalized olefins and a tandem amination-reduction process. Amino acids and amino acid derivatives present many interesting physical and chemical properties finding many uses in the automotive, fuel, electronic, and textile industries.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: September 15, 2020
    Assignee: Umicore AG & Co. KG
    Inventors: Adam M. Johns, Jessica R. Herron, Richard L. Pederson, Thay A. Ung, Ba L. Tran, Daryl P. Allen
  • Patent number: 10774036
    Abstract: The invention relates to a new enantioselective process for producing useful intermediates for the manufacture of NEP inhibitors or prodrugs thereof, in particular NEP inhibitors comprising a ?-amino-?-biphenyl-?-methylalkanoic acid, or acid ester, backbone.
    Type: Grant
    Filed: December 20, 2017
    Date of Patent: September 15, 2020
    Assignee: Novartis AG
    Inventors: Florian Karl Kleinbeck-Riniker, Tobias Kapferer, Hongyong Kim, Jie Ku, Kurt Laumen, Yunzhong Li, Wei Peng, Thomas Ruch, Thierry Schlama, Yao Yang
  • Patent number: 10774037
    Abstract: The present invention relates to a method for producing a specified ?-amino acid, the method including allowing a specified ?-amino acid amide and water to react with each other in the presence of a zirconium compound which contains zirconium and at least one metal element selected from the group consisting of lithium, nickel, copper, zinc, cesium, barium, hafnium, tantalum, cerium, and dysprosium.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: September 15, 2020
    Assignee: SHOWA DENKO K.K.
    Inventors: Takanori Aoki, Akira Shibuya, Takamitsu Kobayashi, Hideo Miyata, Shinya Tsukamoto, Manabu Kuwajima, Motoki Murai
  • Patent number: 10774038
    Abstract: A process for producing cyanonorbornene of the present invention includes Step 1 of preparing a mixture solution including 0.5% by weight to 28% by weight of methyl bicyclononadiene, with respect to a total amount of 100% by weight of dicyclopentadiene, acrylonitrile, and the methyl bicyclononadiene, in a container, and Step 2 of reacting the bicyclopentadiene with the acrylonitrile in the presence of the methyl bicyclononadiene, in the mixture solution.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: September 15, 2020
    Assignee: MITSUI CHEMICALS, INC.
    Inventors: Shigetoshi Kuma, Tomoya Sanda
  • Patent number: 10774039
    Abstract: The invention relates to a polypeptide comprising an amino acid having a cyclopropene group wherein said cyclopropene group is joined to the amino acid via a carbamate group. Suitably the cyclopropene group is a 1,3-disubstituted cyclopropene such as a 1,3-dimethylcyclopropene. Suitably the cyclopropene group is present as a residue of a lysine amino acid. The invention also relates to methods of making the polypeptides. The invention also relates to an amino acid comprising cyclopropene wherein said cyclopropene group is joined to the amino acid moiety via a carbamate group.
    Type: Grant
    Filed: March 10, 2015
    Date of Patent: September 15, 2020
    Assignee: United Kingdom Research and Innovation
    Inventor: Thomas Elliott
  • Patent number: 10774040
    Abstract: Processes for removing carbon disulfide from product streams containing a sulfide compound are performed by contacting the product stream with an alkanolamine and converting the carbon disulfide to a higher boiling point product, thereby reducing or eliminating carbon disulfide from the product stream. Subsequent removal of the higher boiling point product via distillation can lead to a purified sulfide stream with high purity.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: September 15, 2020
    Assignee: Chevron Phillips Chemical Company LP
    Inventors: Kenneth M. Lassen, Michael S. Matson, Daniel M. Hasenberg, Dave Schwierman
  • Patent number: 10774041
    Abstract: The present invention relates to an improved process for the preparation of Apremilast of formula (I).
    Type: Grant
    Filed: January 27, 2017
    Date of Patent: September 15, 2020
    Inventors: Ravi Ponnaiah, Praveen Kumar Neela, Madanlal Anandkumar Lahoti, Srinivas Pardha Gavini Saradhi
  • Patent number: 10774042
    Abstract: The invention particularly relates to crystalline (solid) forms of N-[2-[(1S)-1-(3-ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-1,3-dioxo-2,3-dihydro-1H-isoindol-4-yl]acetamide), i.e. Form N, Form M, Form O and Form P. It also refers to a pharmaceutical composition or dosage form comprising said crystalline forms. The invention also concerns said pharmaceutical composition or dosage form for use in a method of treating a disease or disorder defined in the claims. Finally, the invention pertains to the use of said novel crystalline forms for the preparation of a pharmaceutical composition or dosage form.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: September 15, 2020
    Assignee: ZAKLADY FARMACEUTYCZNE POLPHARMA SA
    Inventors: Monika Oracz, Piotr Garczarek, Przemyslaw Skoczen, Dominika Podwysocka, Marcin Szulc, Arkadiusz Majewski
  • Patent number: 10774043
    Abstract: The present invention discloses compounds of Formula I, wherein each of R1, R2, R3, R4, R5, R6, R7 and R8 are independently selected from H, OBn, OH, CH2OBn, CH2OH, CH3; R9 is selected from alkyl, substituted alkyl, hydroxyl alkyl, alkenyl, benzyl; process for preparation of N-alkylated glycolactam compounds of Formula I and their use for the synthesis of piperidine alkaloids and their analogues.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: September 15, 2020
    Assignee: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH
    Inventors: Asish Kumar Bhattacharya, Hemender Rami Chand
  • Patent number: 10774044
    Abstract: The invention generally relates to conducting reactions in Leidenfrost-levitated droplets.
    Type: Grant
    Filed: June 5, 2017
    Date of Patent: September 15, 2020
    Assignee: Purdue Research Foundation
    Inventors: Robert Graham Cooks, Christopher Pulliam, Ryan M. Bain
  • Patent number: 10774045
    Abstract: Compounds and compositions that can modulate mitochondrial function in neuronal cells are provided herein, as are methods for using the compounds and compositions to treat or prevent conditions such as Alzheimer's disease. For example, compounds of Formula I, compositions containing the compounds, and methods for using the compounds and compositions are provided herein: wherein X is absent, CH2, or C(O); R1 is H, OH, CN, NO2, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl, amino, C1-3 alkylamino, or di(C1-3 alkyl)amino; R2 is H or C1-6 alkyl; R3 is H, C1-6 alkyl, —C(O)(C1-3 alkyl), or —C(O)O(C1-3 alkyl); R4 is C3-10 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, or 5-10 membered heterocycloalkyl, each optionally substituted by 1, 2, 3, or 4 independently selected R5 groups; and R5 is OH, CN, NO2, halo, C1-3 alkyl, C1-3 haloalkyl, C1-3 alkoxy, C1-3 haloalkoxy, C3-7 cycloalkyl, amino, C1-3 alkylamino, or di(C1-3 alkyl)amino.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: September 15, 2020
    Assignee: Mayo Foundation for Medical Education and Research
    Inventors: Eugenia Trushina, Robert Greenhouse, Kevin Greenman, William Thomas
  • Patent number: 10774046
    Abstract: Some embodiments of the invention include inventive compounds. Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases using the compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., diseases such as cancer). Further embodiments include methods for making the inventive compounds. Other embodiments include PFKFB4 inhibitors and methods of using the same that can target neoplastic cells, including, such as, mechanisms within those cells that relate to the use of the glycolytic pathway. In other embodiments, small molecule PFKFB4 inhibitors are used to disrupt the kinase domain of PFKFB4 and, in some instances, decrease the glucose metabolism and growth of human cancers.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: September 15, 2020
    Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC.
    Inventors: Sucheta Telang, Jason Chesney, John O. Trent, Joseph A. Burlison, Nagaraju Miriyala
  • Patent number: 10774047
    Abstract: The invention provides dimeric quinacrine derivatives and related compounds and compositions, methods of treatment and syntheses. The novel compounds exhibit unexpected anticancer activity and are useful in the treatment of a variety of autophagy-related disorders.
    Type: Grant
    Filed: April 26, 2016
    Date of Patent: September 15, 2020
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Ravi K. Amaravadi, Jeffrey Winkler
  • Patent number: 10774048
    Abstract: The present invention is directed to indazole derivatives, pharmaceutical compositions containing them and their use in the treatment and/or prevention of disorders and conditions ameliorated by antagonizing one or more glucagon receptors, including for example metabolic diseases such as Type II diabetes mellitus and obesity.
    Type: Grant
    Filed: January 8, 2019
    Date of Patent: September 15, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Guozhang Xu, Micheal Gaul, Shyh-Ming Yang, Tianbao Lu, Rui Zhang, Fengbin Song
  • Patent number: 10774049
    Abstract: Disclosed herein are inhibitors of PU.1. The inhibitors are useful for treating disorders associated with abnormal PU.1 levels and function.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignees: Albert Einstein College of Medicine, Georgia State University Research Foundation, Inc.
    Inventors: W. David Wilson, David W. Boykin, Gregory Poon, Ulrich Steidl, Iléana Anthony-Debré
  • Patent number: 10774050
    Abstract: The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A1, X, A2, W1, W2, W3, E, Z, and R4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: September 15, 2020
    Assignee: Purdue Pharma, L.P.
    Inventors: Chiyou Ni, Laykea Tafesse, Jiangchao Yao, Mark A. Youngman, Minnie Park, Bin Shao
  • Patent number: 10774051
    Abstract: A compound represented by Formula (I): wherein or the like Y1 is O or the like; Z1 is C(R4) or N; Z2a is C(R5a) or the like; Z3a is C(R6) or the like; R4, R5a and R6 are each independently a hydrogen atom or the like; R1 is substituted or unsubstituted aromatic carbocyclyl or the like; R2a, R2b, R2c and R2d are each independently a hydrogen atom or the like; X is N(R7a) or the like; R7a is a hydrogen atom or the like; R3 is or the like Ring B is a 6-membered aromatic carbocycle or the like; R9a and R10a are each independently halogen or the like; n is an integer from 1 to 5; m is an integer from 0 to 4; and p1 is an integer from 0 to 3, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: September 15, 2020
    Assignee: SHIONOGI & CO., LTD.
    Inventors: Tomoyuki Ogawa, Hiroyuki Kai, Keiichiro Hirai
  • Patent number: 10774052
    Abstract: The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: September 15, 2020
    Assignees: Celgene CAR LLC, Sanofi
    Inventors: Laura Akullian D'Agostino, Robert Tjin Tham Sjin, Deqiang Niu, Joseph John McDonald, Zhendong Zhu, Haibo Liu, Hormoz Mazdiyasni, Russell C. Petter, Juswinder Singh, Matthieu Barrague, Alexandre Gross, Mark Munson
  • Patent number: 10774053
    Abstract: The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
    Type: Grant
    Filed: October 12, 2018
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Zhenhong R. Cai, Aesop Cho, Ana Zurisadai Gonzalez Buenrostro, Xiaochun Han, Salman Y. Jabri, Ryan McFadden, Yingmei Qi, Johannes Voigt, Hong Yang, Jie Xu, Lianhong Xu
  • Patent number: 10774054
    Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Peter A. Blomgren, Kevin S. Currie, Christian Gege, Jeffrey E. Kropf, Jianjun Xu
  • Patent number: 10774055
    Abstract: A process for preparing, 1,1,3-trioxo-1,2-benzothiazole-6-carboxamide of formula (I) comprising: (a) oxidizing 2,5-dimethyl-benzenesulfonamide of formula (II) in the presence of an oxidizing agent to receive 2-sulfamoyl-terephthalic acid of formula (III); (b) converting the formed 2-sulfamoyl-terephthalic acid of formula (III) to receive 2-sulfamoyl-terephthalic acid derivative of formula (IV); and (c) reacting the resulting 2-sulfamoyl-terephthalic acid derivative of formula (IV) with ammonia (NH3) or ammonium containing-salt; wherein R represents OR? or CI and R? represents a branched or non-branched C1-C12 alkyl.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Adam Agan Ltd.
    Inventors: Bijukumar Gopinathan Pillai, Sima Mirilashvili, Yaniv Barda, Bhavinkumar P. Hamirani, Bhoopal Meka, Sreedevi Mannam
  • Patent number: 10774056
    Abstract: Provided herein are substituted piperazine compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders associated with HDAC1 and/or HDAC2 activity.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: September 15, 2020
    Assignee: REGENACY PHARMACEUTICALS, INC.
    Inventors: John H. van Duzer, Ralph Mazitschek
  • Patent number: 10774057
    Abstract: A process for preparing ethene oxide comprising providing a liquid feed stream comprising ethene, hydrogen peroxide, and a solvent; passing the liquid feed stream into an epoxidation zone comprising a catalyst comprising a titanium zeolite comprising zinc and having framework type MWW, and subjecting the liquid feed stream to epoxidation reaction conditions in the epoxidation zone, obtaining a reaction mixture comprising ethene oxide, water, and the solvent; removing an effluent stream from the epoxidation zone, the effluent stream comprising ethene oxide, water and the solvent.
    Type: Grant
    Filed: July 12, 2017
    Date of Patent: September 15, 2020
    Assignee: BASF SE
    Inventors: Andrei-Nicolae Parvulescu, Ulrich Mueller, Joaquim Henrique Teles, Dominic Riedel, Markus Weber, Yan Li
  • Patent number: 10774058
    Abstract: A process for preparing D-glucaro-6,3-lactone from a salt of D-glucaric acid is provided. The process includes: adding a mineral acid to a pre-cooled solution including a salt of D-glucaric acid, water, and acetone to obtain a crude mixture; allowing the crude mixture to rise to a temperature in a range of ?15° C. to ?35° C. and stirring the crude mixture; filtrating the crude mixture and washing with an acetone and water solvent mixture to obtain a filtrate; concentrating the filtrate under vacuum pressure to obtain a concentrated filtrate having a water content in a range of ?20.0 wt. % to ?40.0 wt. %, relative to an overall weight of the concentrated filtrate; storing the concentrated filtrate at a temperature in a range of ?0° C. to ?5° C., and optionally repeating the concentrating and storing steps to obtain a precipitate comprising D-glucaro-6,3-lactone.
    Type: Grant
    Filed: February 7, 2018
    Date of Patent: September 15, 2020
    Assignee: BASF SE
    Inventors: Abhijeet Roy, Dominik Ohlmann, Rahul Mulay, Priti Kulkarni, Vijay Narayanan Swaminathan
  • Patent number: 10774059
    Abstract: The disclosures herein provide compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, enantiomers, stereoisomers, solvates, and hydrates thereof. These compounds may be formulated as pharmaceutical compositions. The pharmaceutical compositions may be formulated for oral administration, intravenous, spray, parenteral, lozenge, solution, syrup, sachet, transdermal administration, or injection. Such compositions may be used to treatment of inflammation or its associated complications.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Cellix Bio Private Limited
    Inventor: Mahesh Kandula
  • Patent number: 10774060
    Abstract: The present invention disclose a simple and high yielding process of Oxone-acetone mediated metal free syn-dihydroxylation of benzo fused olefins of formula (II) to obtain library of dioxolo compounds of formula (I). The invention further disclose a simple and high yielding process of Oxone-acetone mediated metal free syn-dihydroxylation of stilbene and its derivatives of formula (III) thereof. Also disclosed herein is Wacker-type oxidation of benzo-fused olefins of formula (X). The invention further disclose compounds of formula (I) which can be useful for the treatment of HIV, cancer or malaria.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: September 15, 2020
    Assignee: Council of Scientific & Industrial Research
    Inventors: Chepuri Venkata Ramana, Ravindra Suresh Phatake
  • Patent number: 10774061
    Abstract: The invention relates to a liquid-crystalline medium, preferably having a nematic phase and dielectric anisotropy of 0.5 or more, which comprises one or more compounds of formula S in which denotes and to the use thereof in an electro-optical display, particularly in an active-matrix display based on the IPS or FFS effect, to displays of this type which contain a liquid-crystalline medium of this type, and to the use of the compounds of formula S for the improvement of the transmission and/or response times of a liquid-crystalline medium which comprises one or more additional mesogenic compounds.
    Type: Grant
    Filed: June 28, 2018
    Date of Patent: September 15, 2020
    Assignee: Merck Patent GmbH
    Inventors: Atsutaka Manabe, Constanze Brocke, Brigitte Schuler, Ramin Tavakoli
  • Patent number: 10774062
    Abstract: An object of the present invention is to provide a photocuring method, which makes it possible to rapidly and efficiently obtain a crosslinked product (resin), a compound used in the photocuring method, and a photocuring resin composition containing the compound. The present invention relates to a photocuring method, which comprises a step 1 and a step 2 performed after the step 1, a compound used in the photocuring method, and a photocuring resin composition containing the compound. Step 1: this is a step in which in the presence of (A) compound having a carbonyl group generating a radical by photoirradiation and a carboxyl group decarboxylated by photoirradiation, (B) silane coupling agent having a mercapto group or a (meth)acryl group is reacted with (C) water under acidic conditions to obtain (D) silane compound having a mercapto group or a (meth)acryl group and at least one silanol group.
    Type: Grant
    Filed: January 25, 2017
    Date of Patent: September 15, 2020
    Assignees: FUJIFILM Wako Pure Chemical Corporation, TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Nobuhiko Sakai, Kosuke Yanaba, Shigeaki Imazeki, Koji Arimitsu
  • Patent number: 10774063
    Abstract: Targeting uncontrolled cell proliferation and resistance to DNA damaging chemotherapeutics with at least one reagent has significant potential in cancer treatment. Replication Protein A, the eukaryotic single-strand (ss) DNA binding protein, is essential for genomic maintenance and stability via roles in both DNA replication and repair. Reported herein are small molecules that inhibit the in vitro, in vivo, and cellular ssDNA binding activity of RPA, thereby disrupting the eukaryotic cell cycle, inducing cytotoxicity and increasing the efficacy of chemotherapeutic agents damage DNA, and/or disrupt its replication and/or function. These results provide new insights into the mechanism of RPA-ssDNA interactions in chromosome maintenance and stability. This represents a molecularly targeted eukaryotic DNA binding inhibitor and demonstrates the utility of targeting a protein-DNA interaction as a means of studying the cell cycle and providing a therapeutic strategy for cancer treatment.
    Type: Grant
    Filed: November 13, 2015
    Date of Patent: September 15, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventor: John J. Turchi
  • Patent number: 10774064
    Abstract: Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: September 15, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: Birgitte Langer Eriksen, Magnus Gustafsson, Charlotte Hougaard, Thomas Amos Jacobsen, Martin R. Jefson, Gregg F. Keaney, Jessica Klein, Janus Schreiber Larsen, John A. Lowe, III, John M. McCall, Dorte Strøbæk, Nadia Lybøl von Schoubye
  • Patent number: 10774065
    Abstract: The present invention relates to compounds of formula I: in which m, Y1, Y2, Y3, R1, R2a, R2b, R3a, R3b, R4a, R4b, R5a and R5b are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: September 15, 2020
    Assignee: NOVARTIS AG
    Inventors: Christine Hiu-Tung Chen, Zhuoliang Chen, Jorge Garcia Fortanet, Denise Grunenfelder, Rajesh Karki, Mitsunori Kato, Matthew J. LaMarche, Lawrence Blas Perez, Travis Matthew Stams, Sarah Williams
  • Patent number: 10774066
    Abstract: Aspects of the present disclosure include prodrugs of compounds that activate Nrf2. Such prodrugs find use in the treatment of autoimmune and inflammatory diseases and disorders, such as for example psoriasis and multiple sclerosis. Embodiments of the present disclosure also relate to pharmaceutical compositions that include these prodrugs, methods of using these prodrugs in the treatment of various diseases and disorders, processes for preparing these prodrugs and intermediates useful in these processes.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: September 15, 2020
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Jiaxin Yu, Beth Fernandez, Gary Park, Ihab Darwish
  • Patent number: 10774067
    Abstract: An amorphous form of 9-ethyl-6,6-dimethyl-8-(4-morpholin-4-yl-piperidin-1-yl)-11-oxo-6,11-dihydro-5H-benzo[b]carbazole-3-carbonitrile and a solid dispersion containing the amorphous form can be used extremely advantageously as drugs for oral administration.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 15, 2020
    Assignee: Chugai Seiyaku Kabushiki Kaisha
    Inventors: Koji Shiraki, Tadanobu Nakayama, Tomoaki Ota
  • Patent number: 10774068
    Abstract: Disclosed herein are compounds, compositions, and methods of their use for the treatment of diabetes.
    Type: Grant
    Filed: June 24, 2016
    Date of Patent: September 15, 2020
    Assignees: THE SCRIPPS RESEARCH INSTITUTE, UNIVERSITÄT BREMEN
    Inventors: Hank Michael James Petrassi, Murali Mohan Reddy Peram Surakattula, Kathrin Maedler, Amin Ardestani, Jason T. Roland, Tyler D. Baguley, Matthew S. Tremblay, Weijun Shen, Peter G. Schultz, Arnab K. Chatterjee
  • Patent number: 10774069
    Abstract: Described herein are crystalline forms of pharmaceutically acceptable salts of the lysyl oxidase-like 2 (LOXL2) inhibitor (3-(4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yloxy)phenyl)((3R,4R)-3-fluoro-4-hydroxypyrrolidin-1-yl)methanone. Also described are methods of making the LOXL2 inhibitor, pharmaceutical compositions and medicaments comprising the LOXL2 inhibitor, and methods of using the LOXL2 inhibitor in the treatment of conditions, diseases, or disorders associated with LOXL2 activity.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: September 15, 2020
    Assignee: PHARMAKEA, INC.
    Inventors: David Lonergan, Kevin Ross Holme, Martin W. Rowbottom
  • Patent number: 10774070
    Abstract: Described herein are compounds, such as compounds of Formula (I) and pharmaceutically acceptable salts thereof, that inhibit wild-type RET and its resistant mutants, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions, e.g.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 15, 2020
    Assignee: BLUEPRINT MEDICINES CORPORATION
    Inventors: Natasja Brooijmans, Lucian V. DiPietro, Paul E. Fleming, Joseph L. Kim, Steven Mark Wenglowsky, Yulian Zhang
  • Patent number: 10774071
    Abstract: Compounds and methods of using said compounds singly or in combination with additional agents and compositions of said compounds for the treatment of cancer are disclosed.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: September 15, 2020
    Assignee: Gilead Sciences, Inc.
    Inventors: Evangelos Aktoudianakis, Aesop Cho, Michael Graupe, Lateshkumar Thakorlal Lad, Paulo A. Machicao Tello, Jonathan William Medley, Samuel E. Metobo, Devan Naduthambi, Barton W. Phillips, Scott Preston Simonovich, Peiyuan Wang, William J. Watkins, Jie Xu, Kin Shing Yang, Christopher Allen Ziebenhaus
  • Patent number: 10774072
    Abstract: The present invention relates to a method for producing N-substituted sulfonamide compounds including a step of reacting a sulfonamide compound of general formula (1) with a halogenated organic compound of general formula (2) in the presence of cesium carbonate or potassium carbonate in an organic solvent to produce an N-substituted sulfonamide compound of general formula (3).
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: September 15, 2020
    Assignee: UBE INDUSTRIES, LTD.
    Inventors: Yasuhito Yamamoto, Masayoshi Oue, Yukinori Wada